Cited by 262Ovarian cancer diagnosis and treatmentIntraperitoneal and Appendiceal MalignanciesCancer Cells and Metastasis

The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.

The untapped potential of ascites in ovarian cancer research and treatment

Open access

Ford, Caroline Elizabeth, Werner, Bonnita, Hacker, Neville Frederick, Warton, Kristina·2020·British Journal of Cancer

DOI 10.1038/s41416-020-0875-xPMC PMC7341795

Open this paper in CoChat — free account Open PDF

Abstract

The build-up of fluid in the peritoneal cavity-ascites-is a hallmark of ovarian cancer, the most lethal of all gynaecological malignancies. This remarkable fluid, which contains a variety of cellular and acellular components, is known to contribute to patient morbidity and mortality by facilitating metastasis and contributing to chemoresistance, but remains largely under-researched. In this review, we will critically analyse the evidence associating ascites with metastasis and chemoresistance in ovarian cancer and provide an update on research in the field. We will argue the case for ascites as a unique and accessible substrate for tracking tumour progression and for translational research that will enhance our understanding of this cancer and lead to improvements in patient outcomes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41416-020-0875-x

Cites

111 of 111 references verified0 citation errors · 0 not checkable

Statistics

Fig. 1 Abdominal accumulation of ascites fluid in ovarian cancer patients. The fluid contains tumour cells, non-tumour cells, circulating free DNA (cfDNA) and signalling molecules. CD-95L CD-95 ligand, OPG osteoprotegerin.CC BY · PubMed Central

Fig. 2 Mechanism of ascites build-up in ovarian cancer. Increased vascular permeability and impaired drainage drive the accumulation of ascites fluid.CC BY · PubMed Central

Fig. 3 Three different sized spheroids isolated from a patient with low-grade serous ovarian cancer (LGSOC). a) large spheroid b) medium spheroid c) small spheroid. Spheroids stained with Trypan Blue. Black bar = 100 µM. Unpublished data (B.W.).CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C. D., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,468
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M. W., Reinhard, F., Zhang, C. C., Shipitsin, M. V., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,839
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Liquid biopsies come of age: Towards implementation of circulating tumour DNA
Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R., & Rosenfeld, N. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.7 · Cited by 2,809
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Vergote, I. B., Trope, C. G., Amant, F. C., Kristensen, G. B., Ehlen, T., Johnson, N. P., Verheijen, R. H. M., van der Burg, M. E. L., Lacave, Á. J., Panici, P. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908806 · Cited by 2,538
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H. Q., Mannel, R. S., Homesley, H. D., Fowler, J. M., Greer, B. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104390 · Cited by 2,413
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, É., Kristensen, G. B., Carey, M. S., Beale, P. J., Cervantes, A. M. R., Kurzeder, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103799 · Cited by 2,181
Ovarian Cancer Development and Metastasis
Lengyel, E. R. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.100105 · Cited by 1,702
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
Pujade-Lauraine, É., Hilpert, F., Weber, B. E., Reuß, A., Poveda, A. M., Kristensen, G. B., Sorio, R., Vergote, I. B., Witteveen, P. O., Bamias, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4489 · Cited by 1,660

Show all 110 references

Sorted by citations

Items 201–262 of 262

Polymer Nanoparticle Design for Ovarian Cancer Therapies
Snyder, C. S. (2021) · Deep Blue (University of Michigan) · doi:10.7302/1377
Biomarkers in endometriosis: from diagnosis to treatment
Sousa, A. C., & Salumbo, J. (2022) · RevSALUS - Revista Científica da Rede Académica das Ciências da Saúde da Lusofonia · doi:10.51126/revsalus.v4isup.320
Select Per- and Polyfluoroalkyl Substances (PFAS) Induce Resistance to Carboplatin in Ovarian Cancer Cell Lines
(NTP), N. T. P. (2022) · Chemical Effects in Biological Systems (CEBS) · doi:10.22427/ntp-data-025-00001-0002-000-0
The Effect of Bone Marrow Mesenchymal Stem Cells-Exosomes (BMSC-EXO) on Tumor Angiogenesis and Its Mechanism in Ovarian Cancer Microenvironment
Huang, H., Cheng, M., & Zhu, X. (2022) · Journal of Biomaterials and Tissue Engineering · doi:10.1166/jbt.2022.3016
Long-term results of the enzyme glutation system activity in experimental ovarian cancer
Yershova, L. I., Yeromenko, R. F., Savytskyi, І. V., Alexandryna, T., & Sarakhan, L. (2022) · Journal of Education Health and Sport · doi:10.12775/jehs.2022.12.02.035
Polyunsaturated Fatty Acids Promote Protumoral Macrophage Polarization via a RhoA-YAP1 Signaling Pathway in the Ovarian Cancer MicroenvironmentPreprint
Chan, D. W., Wang, H., Yung, M. M. H., Yang, X., Chen, F., Chan, W.-S., Siu, M. K. Y., Long, R., Liang, Y., Xu, D., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2384228/v1
Data from Metabolic Alterations and WNT Signaling Impact Immune Response in HGSOC
Arend, R. C., Scalise, C. B., Gordon, E. R., Davis, A. M., Foxall, M. E., Johnston, B. E., Crossman, D. K., & Cooper, S. J. (2023) · doi:10.1158/1078-0432.c.6532637.v1
Significance of Ascites Cytology in Early Diagnosis of the Nature of Ovarian Malignancy
聂, 梦. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.134911
Value of Forkhead Box A1 (FOX A1) Immunohistochemical Expression in Epithelial Ovarian Carcinoma
Mohamed, A. H., Mustafa, N. A. M., Harb, O. A., & Mohamed, A. F. (2023) · The Egyptian Journal of Hospital Medicine · doi:10.21608/ejhm.2023.297802
Ascites in malignant ovarian cancer confer ovarian cancer cells chemoresistance to platinum. Combination treatment with crizotinib and 2-hydroxyestradiol restores platinum sensitivityPreprint
Carmi, Y. K., Agbarya, A., Khamaisi, H., Farah, R. E., Shechtman, Y., Korobochka, R., Gopas, J., & Mahajna, J. A. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.24.559160
The correlation of PD-L1 expression in cytological and histological material of serous high-grade ovarian cancer
Jovanović, L., Cirkovic, A. M., Nikolić, L., Jović, M., Mikić, D., Milenković, S. J., & Janković, R. (2023) · Srpski medicinski casopis Lekarske komore · doi:10.5937/smclk4-46109
Participance in time of the different stages of medical help is the necessary factor for the success of realization of practical medical activity (with the description of own observations of ovarian cancer clinical case and its using at classes in State l
Рудіченко, В. М., Khomenko, I. P., Reizin, V. I., Mashchenko, O. I., Reizin, D. V., Sokolenko, A. L., & Torpan, V. V. (2023) · Medicine of Ukraine · doi:10.37987/1997-9894.2023.4-5(270-271).294027
PD-1 + CD8 + TILs and CD57 + CD8 + TALs are associated with Prognosis of Patients with Advanced HGSOCPreprint
He, T., Zhang, J., Zeng, L., Yin, Z., Shang, C., Yu, B., Zhang, X., Yang, X., Xue, L., & Guo, H. (2024) · Research Square · doi:10.21203/rs.3.rs-3956824/v1
The prion-like protein Doppel: A soluble biomarker steering ovarian cancer’s peritoneal to circulatory disseminationPreprint
Azam, Z., Zhang, X., Wahab, R., Hasan, M. M., Kang, B., Hassan, M. M., Karim, M., Choi, J. U., Rana, M., Zhang, J. ‐., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.26.605386
Effectiveness and Safety of Cell-Free and Concentrated Ascites Reinfusion Therapy in the Treatment of Gynecological Malignancy-Related Ascites: A Systematic Review and Meta-Analysis
Zhao, S., Ge, Y., Lv, Y., & Lu, C. (2024) · Journal of Clinical Question · doi:10.69854/jcq.2024.0002
Non-Coding RNAs in Peritoneal Carcinomatosis: From Bench to Bedside
Bohošová, J., Ashraf, N. S., Slabý, O., & Călin, G. A. (2024) · Cancers · doi:10.3390/cancers16172961
A novel approach for the quantification of single-cell adhesion dynamics from microscopy imagesPreprint
Cortesi, M., Li, J., Liu, D., Guo, T., Dokos, S., Warton, K., & Ford, C. E. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.08.616409
Ascitic Shear Stress Activates GPCRs and Downregulates Mucin 15 to Promote Ovarian Cancer MalignancyPreprint
Mehta, G., van der Horst, E., Cotter, L., Bonini, M., Novak, C., Treacher, N., Zhang, Y., Jackson, Z., Narayanan, I. V., Wuchu, F., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-5160301/v1
Interventions in Palliative Care
Malik, S., & Sahni, V. R. (2024) · Springer eBooks · doi:10.1007/978-981-97-4098-7_18
Preoperative Findings of Ascites, Liver Involvement, and Pleural Effusion Can Predict Surgical Outcomes in Patients with Advanced Epithelial Ovarian Cancer
Budiana, I. N. G., Mahendra, I. N. B., & Wiraputra, I. B. M. A. (2024) · European Journal of Medical and Health Sciences · doi:10.24018/ejmed.2024.6.6.2226
Long-term patient-derived ovarian cancer organoids closely recapitulate tumor of origin and clinical responsePreprint
Thorel, L., Dolivet, É., Morice, P., Florent, R., Divoux, J., Perréard, M., Lecouflet, L., Desmartin, G., Alagama, C. M., Giffard, F., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.10.631512
Assessing Autophagy Activation in Advanced Ovarian Cancer Using Ascitic Fluid: A Feasibility Study
Goenka, L., Rajappa, M., Gochhait, D., Manivannan, P., Chaturvedula, L., Charles, L., Goud, A. C., Dubashi, B., Kayal, S., & Ganesan, P. (2025) · Cureus · doi:10.7759/cureus.79371
Ultrasound-guided transversus abdominis plane block as an adjunctive anesthesia technique in elderly patients with combined massive ascites: a case report and literature review
Zhang, L., Liu, A., Wang, L., Zhang, Y., & Hu, Z. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1541462
Malignant ascites enhance γδ T cell cytotoxicity towards ovarian cancer via modulating chemokines secretion from the cancer cells that recruits γδ T cellsPreprint
Yang, Z., Liu, Y., Zheng, M., Li, H., Cui, R., Wang, P., He, T., Guo, H., Zhou, Y., Lin, J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.05.641778
HO-3867 mediated modulation of Extracellular vesicles and Tumor microenvironment: A novel immunotherapeutic strategy for ovarian cancerPreprint
Yadagiri, G., Chakrapani, L. N., Sundaram, S., Velasquez, J., Hughes, T. L., Vendrell, G. S., Bognár, B., Wang, Q., O’Malley, D. M., Cohn, D. E., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.16.653814
RHOV Is a Detachment-Responsive Rho GTPase Necessary for Ovarian Cancer Peritoneal Metastasis
Elhaw, A. T., Tang, P. W., Cheng, Y.-Y., Kamlapurkar, S., Javed, Z., Al-Saad, S., White, S. R., Abdelnaby, A. E., Khan, H., Choi, A. S., et al. (2026) · Cancer Research · doi:10.1158/0008-5472.can-25-4056
Chemotherapy Induces an IL1β-dependent Neutrophil Recruitment that Promotes Chemoresistance in Metastatic Ovarian CancerPreprint
Miyamoto, T., Ye, Y., Manning, B. S., Murphy, B., Minakuchi, M., Hamada, K., Mizuno, R., Taki, M., Yamanoi, K., Murakami, R., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.21.677600
ASCITES IN GASTROINTESTINAL CANCERS: A REVIEW OF SYMPTOMATIC TREATMENT METHODS AND THEIR EFFECTIVENESS
Skowron, W., Kalita, M., Kania, K., & Sosińska, A. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.4064
Targeting mitochondria for treatment of ovarian cancer
Kiran, N. S., Yashaswini, C., Chatterjee, A., Basu, B., Kashid, V. A., & Prajapati, B. G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33536-5.00002-x
Bidirectional Association between Atrial Fibrillation and Ovarian Cancer: Evidence from the UK Biobank and Mendelian Randomization
Zhang, Z., Zhang, N., Guo, X., Tao, Z., Wu, C., Liu, Q., Ding, L., Chen, W., Zhong, Y., Jiang, M., et al. (2025) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-25-0949
Additional file 1 of Hsa_circ_0000497 and hsa_circ_0000918 contributed to peritoneal metastasis of ovarian cancer via ascites
Luo, N., Sulaiman, Z., Wang, C., Ding, J., Chen, Y., Liu, B., Cheng, Z., & Liu, S. (2022) · Figshare · doi:10.6084/m9.figshare.19746068
Additional file 1 of Polyunsaturated fatty acids promote M2-like TAM deposition via dampening RhoA-YAP1 signaling in the ovarian cancer microenvironment
Wang, H., Yung, M. M. H., Xuan, Y., Chen, F., Chan, W., Siu, M. K., Long, R., Jia, S., Liang, Y., Xu, D., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26943774
Robust scoring system to evaluate animal well-being in murine orthotopic breast cancer and ovarian cancer modelsPreprint
Al-Khaledy, R., Watanabe, M., Shukla, R., Mashouri, L., Stone, E. M., & Badeaux, M. D. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.18.695300
Exploring the impact of microbial dysbiosis on ovarian cancer and the therapeutic potential of probiotics
Li, C., Tu, N., Ning, X., Cong, Y., Wu, F., Zhang, X., Li, R., Xu, Y., Wang, B., Jin, L., et al. (2026) · Open Research (University of Surrey) · doi:10.1002/viw.20250192
Mechanistic insights into EOC-PMCs-Induced macrophage polarization via the Galnt15-PPARγ pathway
Liu, S., Li, H., & Li, X. (2026) · Journal of Ovarian Research · doi:10.1186/s13048-026-02002-3
HO-3867 reprograms the tumor microenvironment through extracellular vesicle regulation in ovarian cancer
Yadaigiri, G., Chakrapani, L. N., Sundaram, S., Velasquez, J., Hughes, T. L., Vendrell, G. S., Bognár, B., Wang, Q., O’Malley, D. M., Cohn, D. E., et al. (2026) · Academia oncology. · doi:10.20935/acadonco8118
External Evaluation of a Predictive Model of Suboptimal Cytoreduction in Advanced Ovarian Cancer
Serra, A., Gual, M. V. I., Climent, M. T., Bebia, V., Gil‐Moreno, A., Díaz‐Feijoó, B., Veiga, N., Muruzábal, J. C., González, G. L., Tejerizo-García, A., et al. (2026) · Diagnostics · doi:10.3390/diagnostics16040624
Perioperative trajectories of acute-phase proteins and their association with major postoperative complications in advanced ovarian cancer
Hunde, D., Kofoed, N. G., Hassan, M. U., Wedin, M., Kannisto, P. M., Asp, M., & Salehi, S. (2026) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2026.111509
A replenishable peritoneal implant for localized delivery and peritoneal fluid sampling in ovarian cancer
Sheedy, A., Shetty, M., Weis, A., Bendzick, L. E., Stenger, T. D., Ni, Z., Kennedy, P. R., Myers, J. A., Ward, N., Trask, L., et al. (2026) · Device · doi:10.1016/j.device.2026.101050
Mapping immunosuppressive terrain in high-grade serous ovarian cancer: tumor-intrinsic, stromal, and spatial drivers of therapy response
Liu, S., Jiang, R., Li, Z., Tian, Y., Liu, W., Du, Y., Liu, S., Li, B., & Huang, X. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01392-3
Subclonal β-catenin/YAP signaling heterogeneity accelerates ovarian cancer metastasis through a senescence-associated secretory phenotype
To, S. K. Y., Yang, Y., Shi, Z., Fung, K., Lai, S. L., Li, J. J. X., Ip, P. P. C., & Wong, A. S. T. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08737-7 · Cited by 1
Flavonoids from Clitoria ternatea as Promising Therapeutic Agents against Ovarian Cancer
Shenoy, K. M., Rathi, E., Mallya, P., Sangamesh, V. C., Prabhu, P. P., Lewis, S. A., Govindarajan, R., & Kini, S. G. (2026) · F1000Research · doi:10.12688/f1000research.178795.1
Upfront Cytoreductive Surgery as a Bridge to Systemic Therapy for Recurrent Peritoneal Dissemination of Ovarian Angiosarcoma: A Pediatric Case Report
Matsumoto, M., Sasaki, T., Goto, Y., Shinkai, T., Fukushima, H., Takada, H., Shikama, A., Kobayashi, Y., Miyazawa, D., Watanabe, M., et al. (2026) · Surgical Case Reports · doi:10.70352/scrj.cr.26-0128
TNFSF15 Promotes Vascular Normalization and Tertiary Lymphoid Structure Formation in Experimental Ovarian Cancer
Wang, J.-Y., Wang, Y., Zhang, L. K., Weng, S.-T., Cui, H., Zhang, Z., & Li, L. (2026) · The FASEB Journal · doi:10.1096/fj.202600170r
Immune Evasion in Ovarian Cancer Peritoneal Metastasis: Mechanisms and Biomarker‐Guided Therapeutic Matching
Wang, X., Wang, J., Xiong, D., Cui, S., Wang, Q., Huang, Y., Ding, G., Tang, Y., & Feng, Y. (2026) · Journal of Cellular Physiology · doi:10.1002/jcp.70197
Malignant Ascites in Cancer Patients
Amêndola, C. P., de Magalhães, F. A., khatib, S. H., Jungles, S., Romagnolo, L. G. C., & Araujo, R. L. C. (2026) · Springer eBooks · doi:10.1007/978-3-319-74698-2_73-2
Models of high-grade serous carcinoma of tubo-ovarian origin
Padmanabhan, A., Dwivedi, S. K. D., Merritt, M. A., Verma, P., Buckanovich, R. J., Lang, J. D., Dimmick, H. L., Nephew, K. P., Drapkin, R., Brubaker, L. W., et al. (2026) · Oncology Reviews · doi:10.3389/or.2026.1849834
A narrative review of in vitro studies on the role of reactive oxygen species in aggravating high-grade serous ovarian cancer development
Lee, J., Yeo, S. G., Kim, H. O., Lee, J. M., Singh, M. K., Kim, S. S., Oh, T. I., & Park, D. C. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1878450
WNT8B and -9B promote the survival and dissemination of dormant ovarian cancer cellsPreprint
Zakirova, K., Passos, D. T., Kelawan, C., Roes, M. V., Tahir, R., Hill, M., Kim, S. J., Cecchini, M. J., Mura, M., Shepherd, T. G., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.11.744088
State of the art imaging in ovarian carcinomatosis: how the radiologist can help plan management
Qin, C., Chiu, S., Bharwani, N., & Rockall, A. (2026) · Clinical Radiology · doi:10.1016/j.crad.2026.107460
Targeted Modulation of Abundant Proteins Enhances Proteomic Profiling of Ovarian Cancer Ascites: A Pilot Technical Workflow Comparison
Peng, Z., Lausen, J. D., Benbrook, D. M., Yang, Z., & Ahsan, N. (2026) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6c00382
Ovarian cancer ascites is enriched in Tim4 + macrophage-derived extracellular vesicles carrying a translation-related proteomic signaturePreprint
Gudbergsson, J. M., Strauss, L. M., Wu, Q., Andersen, C. B. F., Søndergaard, E. K. L., Fenton, R. A., & Etzerodt, A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.25.747110
Inflammation Without Effective Immunity in Ovarian Cancer: From Early Translational Observations to Histotype-Dependent Immunometabolic Ecosystems
Neri, M., Ferrari, P. A., Vallerino, V., Sole, G., & Macciò, A. (2026) · Cancers · doi:10.3390/cancers18172782
BRCA1/2-stratified immune profiling of treatment-naive high-grade serous ovarian cancer ascites identifies a Treg-enriched ascitic immune phenotype
Sharma, M., Kaur, B., Rai, B., Sachdeva, M. U. S., Sharma, A. R., Gupta, P., Gautam, U., Bagga, R., & Srinivasan, R. (2026) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2026.07.27
Tumor FAK supports fibrillar collagen expression in ovarian cancer ascites
Ojalill, M., Haanen, T. J., Khan, S. U., Zhang, Y., Boyer, A. D., Chen, X. L., Suwal, U., Rappu, P., Heino, J., McHale, M. T., et al. (2026) · Matrix Biology · doi:10.1016/j.matbio.2026.102053 · Cited by 1
Immunometabolic interactions in gynecologic cancers: Mechanisms, biomarkers, and therapeutic implications
Chuwa, A. H., & Mvunta, D. H. (2026) · Journal of International Medical Research · doi:10.1177/03000605261476189
Near-Infrared Fluorescent Zwitterionic Folic Acid Probe and Serum CA125 for Enhancing Diagnostic Accuracy of Malignant Ovarian Cancer Ascites
Li, M., Liang, D., Zhao, L., Wang, Y., He, X., Zhang, W., Wang, T., Bin, Y., Liu, Y., Ma, R., et al. (2026) · Technology in Cancer Research & Treatment · doi:10.1177/15330338261488986
Peri-diagnostic NSAID use and all-cause mortality in ovarian cancer: nationwide cohort study
Lim, S., Hong, J.-Y., Seo, J.-H., Chung, Y. E., Kim, S. Y., Han, K., & Lee, Y.-Y. (2026) · Journal of Ovarian Research · doi:10.1186/s13048-026-02278-5
Circulating tumor DNA in body fluids for molecular characterization of cancers beyond tissue and blood
Shreenivas, A. V., Limaye, S. A., Cristofanilli, M., Lechner, M., Gaya, A. M., Crook, T. J., Leite, P., Mokbel, K., Schaffrin-Nabe, D., Al-Shamsi, H. O., et al. (2026) · iScience · doi:10.1016/j.isci.2026.117893
Performance Evaluation of a Novel Size-Based Microfluidic Platform for Rare Cell Detection in Blood and Malignant Effusions
Saini, V. M., Öner, E., Cahill, C., Doyle, S., Ardle, A. M., Hurley, S. M., O’Toole, H., Marion, C., MacMahon, L., Henderson, B. D., et al. (2026) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2026.100678
The potential of personalized cancer spheroids in precision therapy
Chakraborty, D., Kundu, S., Rawal, S. K., & Mitra, A. G. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12905-5
Ovarian Cancer Therapy Today and Tomorrow: Unmet Needs, Innovations, and Clinical Pathways
Tannous, J. C., Maimaitiming, D., Yeku, O., Xu, L., & Amoozgar, Z. (2026) · Gynecologic Cancer · doi:10.3390/gynecolcancer1010002

Authors: Ford, C. E., Werner, B., Hacker, N. F., & Warton, K.
Affiliations: UNSW Sydney (AU)
Corresponding author: Ford, Caroline Elizabeth
ORCID: Ford, Caroline Elizabeth
Werner, Bonnita
Hacker, Neville Frederick
Warton, Kristina
Venue: British Journal of Cancer
Publisher: Springer Science and Business Media LLC
Published: 2020-05-08
Volume: 123
Issue: 1
Pages: 9-16
ISSN: 0007-0920 (ISSN-L)
1532-1827
DOI: 10.1038/s41416-020-0875-x
PMC: PMC7341795
OpenAlex: W3022087601
Cited by: 261
References: 110
Citations by year: 2026: 44 · 2025: 51 · 2024: 60 · 2023: 46 · 2022: 42 · 2021: 18
FWCI: 3.95
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0 (tdm)
creativecommons.org/licenses/by/4.0 (vor)
Locations: British Journal of Cancer (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
Funders: Translational Cancer Research Network
Topics: Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords: ascites, ovarian cancer, peritoneal carcinomatosis, chemoresistance, translational research
MeSH terms: Ascites, Female, Humans, Ovarian Neoplasms, Ovary, Biomarkers, Tumor, Proteomics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The untapped potential of ascites in ovarian cancer research and treatment

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks